Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_2789_Библиотеки_им_академика_М_И_Перельмана
.pdf
Литература
https://t.me/medicina_free
Maki D.G. Infections caused by intravascular devices used for infusion therapy:
pathogenesis, prevention, and management // In: Infections associated
with indwelling medical devices / Eds. A.L. Bisno and F.A. Waldovogel. —
nd
ed. — Washington: American Society for Microbiology, D.C., 1994. —
2
P. 155–212.
Maki D.G., Band J.D. A comparative study of polyantibiotic and iodophor
ointments in prevention of vascular catheter-related infection // Amer. J.
Med. — 1981. — V. 70. — P. 739–744.
Marchiam D., Chopra T., Bhargava A. et al. Recent exposure to antimicrobials
and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial
stewardship // Infect. Control Hosp. Epidemiol. — 2012. — V. 33 (8). —
P. 817–830.
Marsh P.D. Are dental diseases examples of ecological catastrophes? // Micro-
biology. — 2003. — V. 149. — P. 279–294.
Maseda E., Suárez-de-la-Rica A., Anillo V. et al. A practice-based observational
study identifying factors associated with the use of highdose tigecycline in
the treatment of secondary peritonitis in severely ill patients // Rev. Esp.
Quimioter. — 2015. — V. 28 (1). — P. 47–53.
Mattila E., Arkkila P., Mattila P.S. et al. Rifaximin in the treatment of recurrent
Clostridium difficile infection // Aliment. Pharmacol. Ther. — 2013. — V. 37
(1). — P. 122–128.
McAllister K., Sheridan-Pereira M., O’Sullivan N. et al. Clinical utility of using
C-reactive protein and procalcitonin as biomarkers for a novel neonatal
sepsis diagnostic platform (ASCMicroPlat) // Critical. Care. — 2012. —
V. 16 (3). — P. 106.
McLaughlin M., Advincula M.R., Malczynski M. et al. Correlations of Antibiotic
use and carbapenem resistance in Enterobacteriaceae // Antimicrob. Agents
Chemother. — 2013. — V. 57 (10). — P. 5131–5133.
McLean J.J.C., Whitely M., Strickler D.J., Fuqua W.C. Evidence of autoinducer
activity in naturally occurring biofilms // FEMS Microbiol. Lett. — 1997. —
V. 154. — P. 259–263.
Murga R., Miller J.M., Donlan R.M. Biofilm formation by gram-negative bac-
teria on central venous catheter connectors: effect of conditioning films
in a laboratory model // J. Clin. Microbiol. — 2001. — V. 39. — P. 2294–
2297.
Neu T.R., Verkerke G.J., Herrmann I.F. et al. Microflora on explanted silicone
rubber voice protheses: taxonomy, hydrophobicity and electrophoretic mobility // J. Appl. Bacteriol. — 1994. — V. 76. — P. 521–528.
Ni W., Han Y., Liu J. et al. Tigecycline Treatment for Carbapenem-Resistant
Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis //
Medicin. (Baltimore). — 2016. — V. 95 (11). — e3126.
Nichols W.W., Evans M.J., Slack M.P.E., Walmsley H.L. The penetration of an-
tibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa // J. Gen. Microbiol. — 1989. — V. 135. — P. 1291–1303.
350
Литература
https://t.me/medicina_free
Nitzan O., Kennes Y., Colodner R. et al. Chloramphenicol use and susceptibility
patterns in Israel: a national survey // Isr. Med. Assoc. J. — 2015. — V. 17
(1). — P. 27–31.
Nitzan O., Suponitzky U., Kennes Y. et al. Is chloramphenicol making a come-
back? // Isr. Med. Assoc. J. — 2010. — V. 12 (6). — P. 371–374.
Nuila F., Cadle R.M., Logan N. et al. Antibiotic stewardship and Clostridium
difficile-associated disease // Infect. Control. Hosp. Epidemiol. — 2008. —
V. 29 (11). — P. 1096–1097.
Nyvad B., Kilian M. Comparison of the initial streptococcal microflora on dental
enamel in caries-active and in caries-inactive individuals // Caries Res. —
1990. — V. 24. — P. 267–272.
O’Toole G.A., Gibbs K.A., Hager P.W. et al. The global carbon metabolism regu-
lator Crc is a component of a signal transduction pathway required for
biofilm development by Pseudomonas aeruginosa // J. Bacteriol. — 2000. —
V. 182. — P. 425–431.
O’Toole G.A., Kaplan H., Kolter R. Biofilm formation as microbial development //
Ann. Rev. Microbiol. — 2000. — V. 54. — P. 49–79.
O’Toole G.A., Kolter R. The initiation of biofilm formation in Pseudomonas fluo-
rescens WCS365 proceeds via multiple, convergent signaling pathways:
a genetic analysis // Mol. Microbiol. — 1998. — V. 28. — P. 449–461.
Oliva A., Mascellino M.T., Cipolla A. et al. Therapeutic strategy for pandrug-re-
sistant Klebsiella pneumonia severe infections: shortcourse treatment with
colistin increases the in vivo and in vitro activity of double carbapenem
regimen // Int. J. Infect. Dis. — 2015. — V. 33. — P. 132–134.
Orsini J., Mainardi C., Muzylo E. et al. Microbiological profile of organisms caus-
ing bloodstream infection in critically ill patients // J. Clin. Med. Res. —
2012. — V. 4 (6). — P. 371–377.
Perichon B., Courvalin P. VanA-type vancomycin-resistant Staphylococcus au-
reus // Antimicrob. Agents Chemother. — 2009. — V. 53 (11). — P. 4580–4587.
Petrof E.O., Khoruts A. From stool transplants to next-generation microbiota
therapeutics // Gastroenterology. — 2014. — V. 146 (6). — P. 1573–1582.
Poulsen L.K., Ballard G., Stahl D.A. Use of rRNA fluores-cence in situ hybridi-
zation for measuring the activity of single cells in young and established
biofilms // Appl. Environ. Microbiol. — 1993. — V. 59. — P. 1354–1360.
Pratt L.A., Kolter R. Genetic analysis of Escherichia coli biofilm formation: defin-
ing the roles of flagella, motility, chemotaxis and type I pili // Mol. Microbiol. — 1998. — V. 30. — P. 285–294.
Prigent-Combaret C., Vidal O., Dorel C., Lejeune P. Abiotic surface sensing and
biofilm-dependent regulation of gene expression in Escherichia coli //
J. Bacteriol. — 1999. — V. 181. — P. 5993–6002.
Puca E., Pipero P., Pilaca A. et al. Evaluation of procalcitonin in patients with
sepsis in Albanian adults // Critical. Care. — 2012. — V. 16 (3). — P. 116.
Queenan A.M., Bush K. Carbapenemases: the versatile betalactamases // Clin.
Microbiol. Rev. — 2007. — V. 20 (3). — P. 440–458.
351
Литература
https://t.me/medicina_free
Raad I. Intravascular-catheter-related infections // Lancet. — 1998. — V. 351. —
P. 893–898.
Rainkie D., Kolber M.R. Probiotics for the prevention of Clostridium difficile //
Can. Fam. Physician. — 2013. — V. 59 (9). — P. 957.
Riedel S. Procalcitonin and antibiotic therapy: Can we improve antimicrobial
stewardship in the intensive care setting? // Care Medicine. — 2012. —
V. 40 (8). — P. 2499–2450.
Rioufol C., Devys C., Meunier G. et al. Quantitative determination of endotoxins
released by bacterial biofilms // J. Hosp. Infect. — 1999. — V. 43. — P. 203–
209.
Roberts A.P., Pratten J., Wilson M., Mullany P. Transfer of a conjugative transpo-
son, Tn5397 in a model oral biofilm // FEMS Microbiol. Lett. — 1999. —
V. 177. — P. 63–66.
Roberts R.B. Streptococcal endocarditis: the viridins and beta hemolytic strep-
tococci // In: Infective endocarditis / Ed. D. Kaye. — 2
Raven Press, 1992. — P. 191–208.
Robinson R.W., Akin D.E., Nordstedt R.A. et al. Light and electron microscopic
examinations of methaneproducing biofilms from anaerobic fixed-bed reactors // Appl. Environ. Microbiol. — 1984. — V. 48. — P. 127–136.
Rupp M.E., Ulphani J.S., Fey P.D., Mack D. Characterization of Staphylococ-
cus epidermidis polysaccharide intercellular adhesin/hemag-glutinin in the
pathogenesis of intravascular catheter-associated infection in a rat model //
Infect. Immun. — 1999. — V. 67. — P. 2656–2659.
Sader H.S., Jones R.N. Antimicrobial susceptibility of Gram-positive bacteria
isolated from US medical centers: results of the Daptomycin Surveillance
Program (2007–2008) // Diagn. Microbiol. Infect. Dis. — 2009. — V. 65
(2). — P. 158–162.
Schaadt R. et al. In Vitro Activity of TR-700, the Active Ingredient of the An-
tibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial Agent //
Antimicrob. Agents Chemother. — 2009. — P. 3236–3239.
Schuchat A. Epidemiology of group B streptococcal disease in the United States:
shifting paradigms // Clin. Microbiol. Rev. — 1998. — V. 11 (3). — P. 497–
513.
Schwan C., Stecher B., Tzivelekidis T. et al. Clostridium difficile toxin CDT in-
duces formation of microtubule-based protrusions and increases adherence
of bacteria // PLoS Pathog. — 2009. — V. 5 (10). — e1000626.
Senbayrak Akcay S., Inan A., Cevan S. et al. Gram-negative bacilli causing infec-
tions in an intensive care unit of a tertiary care hospital in Istanbul, Turkey // J. Infect. Dev. Ctries. — 2014. — V. 8 (5). — P. 597–604.
Shenderov B.A. Metabiotics: novel idea or naturaldevelopment of probiotic con-
ception // Microb. Ecol. Health. Dis. — 2013. — V. 24. — P. 20399.
Shenderov B.A. Modern condition and prospective host microecology investiga-
tions // Microb. Ecol. Health. Dis. — 2007. — V. 19. — P. 145–149.
nd
ed. — New York:
352
Литература
https://t.me/medicina_free
Shiau A.-L., Wu C.-L. The inhibitory effect of Staphylococcus epidermidis slime
on the phagocytosis of murine peritoneal macrophages is interferon-independent // Microbiol. Immunol. — 1998. — V. 42. — P. 33–40.
Singer M. Cellular Dysfunction in Sepsis // Clin. Chest. Med. — 2008. — V. 29
(4). — P. 655–60.
Singer M. Mitochondrial function in sepsis: acute phase versus multiple organ
failure // Critical. Care Med. — 2007. — V. 35 (9). — S. 441–448.
Sissons C.H. Artificial dental plaque biofilm model systems // Adv. Dent. Res. —
1997. — V. 11. — P. 110–126.
Sood S. Chloramphenicol — A Potent Armament Against Multi-Drug Resis tant
(MDR) Gram Negative Bacilli? // J. Clin. Diagn. Res. — 2016. — V. 10
(2). — DC01-3.
Souli M., Giamarellou H. Effects of slime produced by clinical isolates of coagu-
lase-negative staphylococci on activities of various antimicrobial agents //
Antimicrob. Agents Chemother. — 1998. — V. 42. — P. 939–941.
Stanley P.M. Factors affecting the irreversible attachment of Pseudomonas aeru-
ginosa to stainless steel // Can. J. Microbiol. — 1983. — V. 29. — P. 1493–
1499.
Steele J., Chen K., Sun X. et al. Systemic dissemination of Clostridium difficile
toxins A and B is associated with severe, fatal disease in animal models //
J. Infect. Dis. — 2012. — V. 205. — P. 384–391.
Stewart P.S. Theoretical aspects of antibiotic diffusion into microbial biofilms //
Antimicrob. Agents Chemother. — 1996. — V. 40. — P. 2517–2522.
Stickler D.J., Morris N.S., McLean R.J.C., Fuqua C. Biofilms on indwelling urethral
catheters produce quorum-sensing signal molecules in situ and in vitro //
Appl. Environ. Microbiol. — 1998. — V. 64. — P. 3486–3490.
Stoodley P., DeBeer D., Lewandowski Z. Liquid flow in biofilm systems // Appl.
Environ. Microbiol. — 1994. — V. 60. — P. 2711–2716.
Suci P.A., Mittelman M.W., Yu F.P., Geesey G.G. Investigation of ciprofloxacin
penetration into Pseudomonas aeruginosa biofilms // Antimicrob. Agents
Chemother. — 1994. — V. 38. — P. 2125–2133.
Surawicz C.M., Brandt L.J., Binion D.G. et al. Guidelines for diagnosis, treatment,
and prevention of Clostridium difficile infections // Amer. J. Gastroenterol. — 2013. — V. 108 (4). — P. 478–498.
Tang B.M.P, Eslick G.D., Craig J.C., McLean A.S. Accuracy of procalcitonin for
sepsis diagnosis in critically ill patients: systematic review and meta-analysis // Lancet Infect. Dis. — 2007. — V. 7 (3). — P. 210–217.
Tokars J.I. Predictive value of blood cultures positive for coagulase-negative
staphylococci: implications for patient care and health care quality assurance // Clin. Infect. Dis. — 2004. — V. 39. — P. 334–341.
Tsai M.H., Chu S.M., Hsu J.F. et al. Risk factors and outcomes for multidrug-
resistant Gram-negative bacteremia in the NICU // Pediatrics. — 2014. —
V. 133 (2). — e322–329.
353
Литература
https://t.me/medicina_free
Tumbarello M., Trecarichi E.M., De Rosa F.G. et al. Infections caused by KPC-
producing Klebsiella pneumoniae: differences in therapy and mortality in
a multicentre study // J. Antimicrob. Chemother. — 2015. — V. 70 (7). —
P. 2133–2143.
Tumbarello M., Viale P., Viscoli C. et al. Predictors of mortality in bloodstream
infections caused by Klebsiella pneumoniae carbapenemase-producing
K. pneumoniae: importance of combination therapy // Clin. Infect. Dis. —
2012. — V. 55 (7). — P. 943–950.
Veenstra D.L., Saint S., Saha S. et al. Efficacy of antiseptic-impregnated central
venous catheters in preventing catheter-related bloodstream infection //
J.A.M.A. — 1999. — V. 281. — P. 261–267.
Viehman J.A., Nguyen M.H., Doi Y. Treatment options for carbapenem-resis-
tant and extensively drug-resistant Acinetobacter baumannii infections //
Drugs. — 2014. — V. 74 (12). — P. 1315–1333.
Vincent F.C., Tibi A.R., Darbord J.C. A bacterial biofilm in a hemodialysis system.
Assessment of disinfection and crossing of endotoxin // ASAIO Trans. —
1989. — V. 35. — P. 310–313.
Vincent J.L., Abraham E. The last 100 Years of Sepsis // Amer. J. Respir. Crit.
Care. Med. — 2006. — V. 173 (3. — P. 56–263.
Vincent J.L., Nelson D.R., Williams M.D. Is worsening multiple organ failure
the cause of death in patients with severe sepsis? // Critical. Care Med. —
2011. — V. 39 (5). — P. 1050–1055.
Walker N., Gupta R., Cheesbrough J. Blood pressure cuffs: friend or foe? //
J. Hosp. Infect. — 2006. — V. 63 (2). — P. 167–169.
Wang I.-W., Anderson J.M., Marchant R.E. Staphylococcus epidermidis adhesion
to hydrophobic biomedical polymer is mediated by platelets // J. Infect.
Dis. — 1993. — V. 167. — P. 329–336.
Ward K.H., Olson M.E., Lam K., Costerton J.W. Mechanism of persistent infec-
tion associated with peritoneal implants // J. Med. Microbiol. — 1992. —
V. 36. — P. 406–413.
Watnick P., Kolter R. Biofilm, City of Microbes // Bacteriology. — 2000. — V. 182
(10). — P. 2675–2679.
Wenisch J.M., Schmid D., Kuo H.W. et al. Hospital-acquired Clostridium difficile
infection: determinants for severe disease // Europ. J. Clin. Microbiol. Infect. Dis. — 2012. — V. 31 (8). — P. 1923–1930.
Widmer A.F., Frei R., Rajacic Z., Zimmerli W. Correlation between in vivo and
in vitro efficacy of antimicrobial agents against foreign body infections //
J. Infect. Dis. — 1990. — V. 162. — P. 96–102.
Wilcox M.H.
Wolfaardt G.M., Lawrence J.R.
, Shetty N., Fawley W.N. et al. Changing epidemiology of Clostridium
difficile infection following the introduction of a national ribotyping-based
surveillance scheme in England // Clin. Infect. Dis. — 2012. — V. 55 (8). —
P. 1056–1063.
, Roberts R.D. et al. Multicellular organization in
a degradative biofilm community // Appl. Environ. Microbiol. — 1994. —
V. 60. — P. 434–446.
354
Литература
https://t.me/medicina_free
Zar F.A., Bakkanagari S.R., Moorthi K.M., Davis M.B. A comparison of vancomy-
cin and metronidazole for the treatment of Clostridium difficile-associated
diarrhea, stratified by disease severity // Clin. Infect. Dis. — 2007. — V. 45
(3). — P. 302–307.
Zhanel G.G., Love R., Adam H. et al. Tedizolid: A Novel Oxazolidinone with
Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens //
Drugs. — 2015. — V. 75. — P. 253–270.
Zips A., Schaule G., Flemming H.C. Ultrasound as a means of detaching bio-
films // Biofouling. — 1990. — V. 2. — P. 323–333.
355
ПРЕДМЕТНЫЙ УКАЗАТЕЛЬ
https://t.me/medicina_free
Абактал 107, 244
Авелокс 110, 161, 223
Авибактам 129, 130, 133
Азитромицин 119, 120, 127, 134, 185,
187–191, 215, 220, 222
Амикацин 37, 105, 108, 126, 159, 178,
197, 207, 234
Аминогликозид 102, 137, 178, 194,
198, 202, 208–210, 212, 224, 229,
230, 326
Аминопенициллин 79, 155
Амоксиклав 31, 79, 109, 223
Амоксициллин 77, 79, 125, 136, 155,
187, 188
Ампиокс 75, 178, 181, 185, 196, 200,
202, 208, 215, 225, 243
Амписид 79, 80
Ампициллин 30–37, 60, 62, 63, 71,
76, 77, 79, 99, 125, 155, 178, 185,
187, 188, 194, 196, 200, 202, 206,
207, 211–213, 215, 220, 222, 224–
226, 229, 230, 234, 238, 242, 246
Амфолип 43
Амфотерицин В 43
Амфотерицин В-липидный
комплекс 43
Анкотил 43
Аугментин 31, 79, 109, 223
Бактрим 161
Бензилпенициллин 28, 74, 125, 141,
154, 184, 187, 193, 194, 196, 200,
202, 212, 222, 224–226, 229, 230,
248, 250
Бисептол 63, 88, 122, 161, 183, 187,
198, 222
Брамитоб 105
Бруламицин 105
Ванкомицин 31, 35, 111–113, 126,
139, 157, 165, 178, 198, 200, 206,
211, 225, 226, 234, 243, 282
Варфарин 118
Вибрамицин 121
Вилимиксин 123
Вильпрофен 119
Вориконазол 43, 118, 183
Гентамицин 62, 76, 104, 126, 158, 185,
187, 190, 194, 200, 202, 206, 207,
211, 213, 215, 220, 222, 226, 229,
234, 238, 239, 242, 243, 246, 248, 250
356
Предметный указатель
https://t.me/medicina_free
Далацин 120
Далбаванцин 32, 129, 130
Даптомицин 49, 115, 126, 177
Джозамицин 119, 120, 187
Динабак 119
Диритромицин 119, 120
Дихлотиазид 137
Доксициклин 121, 161, 185, 194, 196,
249
Дорипенем 95, 97, 126, 132, 176
Дурацеф 83
Заноцин 107
Зефтера 94
Зинацеф 88
Зиннат 79, 88–90, 213
Зинфоро 94, 95
Имипенем 48, 68, 95, 97, 126, 132–
134, 299
Инванз 95
Канамицин 104, 105, 137
Карбапенем 37, 50, 60, 68, 95, 100,
153, 156, 165, 174–176, 178, 198,
206, 209, 234, 243, 255
Карбенициллин 78, 75
Каспофунгин 43, 183
Кетоконазол 43, 178, 215
Кетоцеф 88
Кефзол 83
Клабак 222
Клавуланат 80, 93
Клавулановая кислота 31, 34, 78, 79,
99, 208
Кларитромицин 34, 62, 119, 187, 161,
185, 187, 194, 215, 220, 222
Клафоран 156, 237, 244, 249
Клацид 79, 119, 222, 223
Клиндамицин 41, 120, 178, 215, 216
Ко-амоксиклав 70–80, 99, 155, 174,
178, 185, 194, 196, 200, 202, 206–
212, 215, 220, 222, 225, 229, 230,
234, 242, 246, 248, 250
Ко-амоксициллин 78, 93, 179, 187,
189, 200, 202, 206–208, 229, 234,
238
Колистин 123, 124, 127, 175
Ко-тримоксазол 63, 122, 127, 161,
178, 185, 187, 200, 202, 215, 220,
222
Кубицин 116
Латамоксеф 41
Левомицетин 121
Леворин 42, 183, 199
Левофлоксацин 38, 106, 110, 132,
223
Лендацин 240, 241
Линезолид 49, 113–115, 126, 177,
178, 198, 200, 206, 255
Линкозамиды 120
Линкомицин 120, 178, 185, 200, 202,
215, 220, 222, 225, 226, 230
Макролид 118, 127, 140, 161, 174,
178, 185, 188, 194, 196, 200, 202,
212, 213, 215, 217, 220, 222, 224–
226, 229, 230, 248, 250
Макропен 119
Максипим 94, 136, 157
Мандол 88
Меронем 80, 141, 153
Меропенем 95, 97, 126, 141, 176
Метациклин 121
Метициллин 30, 31, 48, 60, 61, 75,
176, 177, 295
Метраджил 247
Метронидазол 41, 42, 120, 178, 202,
206, 226, 230, 234, 238, 239, 246,
248, 250, 282
Мефоксин 88
Мидекамицин 119, 187, 189, 191
Микамин 183
Микафунгин 43
Миноциклин 38
Моксифлоксацин 106, 110, 132, 190,
223
357
Предметный указатель
https://t.me/medicina_free
Мупироцин (мазь) 313
Небцин 105
Нетилмицин 104, 105, 126, 137
Нетромицин 105
Низорал 43
Нистатин 42, 183, 199
Нитазоксанид 284
5-НОК 106
Оксациллин 30, 31, 60, 61, 71, 75, 98,
125, 150, 154, 178, 185, 196, 200,
202, 208, 211, 212, 215, 225, 226,
229, 243
Оритаванцин 32, 129, 130
Офлоксацин 106, 107
Пефлоксацин 106, 107
Пиперациллин 78, 80, 132, 216, 326,
328
Плазомицин 132
Полимиксин В 123
Полимиксин Е 123
Ристомицин 118, 228, 327
Рифаксимин 284
Рифамицин 284
Рифампицин 118, 228, 327
Ровамицин 119
Рокситромицин 119, 120, 187
Роцефин 156, 240, 241, 244
Рулид 119, 140
Септрин 161, 183, 187, 198, 222
Спарфло 110
Спарфлоксацин 110
Спирамицин 119, 120, 187
Стрептомицин 104, 105, 137
Сульбактам 34, 37, 63, 78–80, 91,
125, 175
Сульфаметоксазол 122
Сумамед 47, 79, 119, 140, 174, 222,
223
Супракс 92
Таваник 110, 161, 223
Тазобактам 78, 80, 129, 130, 132,
216
Тазоцин 80
Таривид 107, 224
Тедизолид 32, 114, 115, 129, 177, 178,
201
Тейкопланин 112, 129
Тейхопланин 327
Телаванцин 116, 177
Тетрациклин 116, 121, 127, 161, 248,
250
Тигециклин 49, 116–118, 127, 175,
177, 282
Тиенам 80, 88, 97, 153
Тикарциллин 80
Тиментин 80
ТОБИ 105
Тобрамицин 104–106, 137, 234
Триметоприм 38
Трифамокс 79, 80
Трихопол 247
Феноксиметилпенициллин 74, 154
Фидаксомицин 282, 284
Финафлоксацин 131
Флагил 247
Флемоклав-солютаб 79
5-Флуцитозин 43
Флуконазол 42, 43, 165, 178, 215,
234, 238, 239
Фортум 85, 108
Фосфомицин 124, 127, 175
Фромелид 222
Фторхинолон 106, 107, 110, 126, 138,
161, 178, 185, 187, 189, 194, 196,
200, 202, 206, 207, 209, 215, 220,
222, 224, 243, 250, 328, 330
Фузидиевая кислота 120
Фузидин 228
Фунгизон 43
Хлорамфеникол 114, 122
Хинолон 106, 275, 330
358
Предметный указатель
https://t.me/medicina_free
Цедекс 92, 244
Цеклор 79, 88, 90, 223
Цепорин (снят с производства) 137
Цефадроксил 83, 109, 155, 213, 224
Цефазолин 60, 63, 69, 75, 82, 83, 99,
155, 184, 185, 187, 189, 194, 211–
213, 215, 220, 224, 225, 229, 241
Цефаклор 88–90, 187, 195, 197, 212,
244
Цефалексин 83, 84, 109, 155, 187,
212, 224, 225, 229
Цефалоридин (снят с производ-
ства) 137
Цефалоспорин I поколения 83, 126,
155, 178, 185, 196, 200, 202, 208,
215, 226, 243
Цефамандол 88, 89, 136, 179
Цефамезин 83
Цефепим 37, 94, 126, 156, 178, 198
Цефиксим 92
Цефокситин 31, 41, 88
Цефоперазон 84, 91, 136, 137, 239
Цефоперазон/сульбактам 37, 63, 69,
80, 89
Цефотаксим 84, 85, 91, 93, 94, 103,
156, 219, 234, 239
Цефтазидим 35, 37, 83, 85, 91–94,
99, 108, 126, 130, 156, 178, 206,
209, 234
Цефтаролин 32, 50, 94, 177
Цефтибутен 92, 244
Цефтобипрол 50, 94, 132
Цефтолозан 130
Цефтриаксон 91, 92, 239
Цефуроксим 88–90, 187
Цефуроксим аксетил 88, 90, 197
Циластатин 299
Ципро 160
Ципробай 107, 187
Ципролет 61, 107, 109, 160, 187, 222,
244
Ципрофлоксацин 37, 61, 63, 106–
110, 126, 160, 178, 187, 197, 198,
200, 206, 209, 210, 213, 226, 230,
234, 242, 243
Цифран 61, 107, 109, 160, 187, 222,
244
Эравациклин 132
Эритромицин 119, 120, 140, 164, 187
Эртапенем 95, 126, 176
Этакриновая кислота 137
359
Соседние файлы в папке Библиотека им академика М.И. Перельмана